Daniel Schmitt, Actuate Therapeutics CEO

A Texas-Illi­nois can­cer biotech search­es for more Se­ries B cap­i­tal two years af­ter ex­ten­sion

A Texas biotech try­ing to treat var­i­ous can­cers, in­clud­ing re­frac­to­ry ones for pe­di­atric pa­tients, is on a wind­ing fi­nanc­ing jour­ney.

About 12 months af­ter dis­clos­ing a “Se­ries B-3” round in au­tumn 2019, the Chica­go-born biotech at­tempt­ed rais­ing $50 mil­lion, but SEC fil­ings show about $14.5 mil­lion of that was se­cured. Then, start­ing in late Sep­tem­ber of this year, Ac­tu­ate Ther­a­peu­tics at­tempt­ed once again to bring in $50 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.